Zanamivir (Relenza) as a safe to use - discussion
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation. More: en.wikipedia.org.
0 opinions, 0 replies
Add your opinion:
Challenge someone to answer this topic:
Invite an OpiWiki user:
OR
Invite your friend via email:
@
click for template
OR
Share it:
Share this discussion via OpiWiki smartlink:
OR
Status:
Active
Views:
1,124
subscribe
For new opinion notification
Voting
(1 vote)
At: debate, forum.